| Literature DB >> 29149593 |
Hidefumi Fukushima1, Kouhei Shimizu2, Asami Watahiki3, Seira Hoshikawa4, Tomoki Kosho5, Daiju Oba6, Seiji Sakano7, Makiko Arakaki4, Aya Yamada8, Katsuyuki Nagashima9, Koji Okabe9, Satoshi Fukumoto4, Eijiro Jimi10, Anna Bigas11, Keiichi I Nakayama12, Keiko Nakayama13, Yoko Aoki6, Wenyi Wei14, Hiroyuki Inuzuka15.
Abstract
Hajdu-Cheney syndrome (HCS), a rare autosomal disorder caused by heterozygous mutations in NOTCH2, is clinically characterized by acro-osteolysis, severe osteoporosis, short stature, neurological symptoms, cardiovascular defects, and polycystic kidneys. Recent studies identified that aberrant NOTCH2 signaling and consequent osteoclast hyperactivity are closely associated with the bone-related disorder pathogenesis, but the exact molecular mechanisms remain unclear. Here, we demonstrate that sustained osteoclast activity is largely due to accumulation of NOTCH2 carrying a truncated C terminus that escapes FBW7-mediated ubiquitination and degradation. Mice with osteoclast-specific Fbw7 ablation revealed osteoporotic phenotypes reminiscent of HCS, due to elevated Notch2 signaling. Importantly, administration of Notch inhibitors in Fbw7 conditional knockout mice alleviated progressive bone resorption. These findings highlight the molecular basis of HCS pathogenesis and provide clinical insights into potential targeted therapeutic strategies for skeletal disorders associated with the aberrant FBW7/NOTCH2 pathway as observed in patients with HCS.Entities:
Keywords: FBW7; Hajdu-Cheney syndrome; NOTCH inhibitor; NOTCH2; SCF E3 ubiquitin ligase; osteoclast; osteoclastogenesis; osteolysis; osteoporosis; ubiquitination
Mesh:
Substances:
Year: 2017 PMID: 29149593 PMCID: PMC5730348 DOI: 10.1016/j.molcel.2017.10.018
Source DB: PubMed Journal: Mol Cell ISSN: 1097-2765 Impact factor: 17.970